Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong
- PMID: 16542729
- PMCID: PMC7112522
- DOI: 10.1016/j.jinf.2006.01.005
Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong
Abstract
Background: The patterns of corticosteroids usage in severe acute respiratory syndrome (SARS) and associated treatment outcomes in Hong Kong were studied.
Method: Patients> or =18 years old who either had not received corticosteroid or had taken corticosteroids within 14 days from symptom onset were included. Patients receiving corticosteroids beyond 15 days or other investigational treatment within 21 days from symptom onset were excluded. Of 1313 eligible patients, 1287 with major corticosteroid dosage-type combinations were analysed.
Results: Crude death rate was lower among 1188 steroid-treated patients compared to 99 patients in Group No Steroid (17.0% vs. 28.3%). Among four corticosteroid groups studied, mortality was lowest in the low-dose oral prednisolone (Group P) and high-dose methylprednisolone (Group MP) groups. On multivariate analysis of the corticosteroid groups, independent factors related to death were: corticosteroid group, older age, co-morbidity, worse chest X-ray score, worse respiratory status at Days 8-10 and higher admission white cell count. Again Groups P and MP had significantly lower adjusted odds ratios for death and lower bacterial and fungal culture rates. Despite worse chest X-ray scores and higher cumulative corticosteroid dosages in Group MP compared to Group P, fewer patients required rescue pulsed corticosteroid. Patients on hydrocortisone (Group HC) had the highest positive culture rates.
Conclusion: We speculate that corticosteroid with higher in-vitro inflammatory potency administered at timing and dosages commensurate with disease severity may be conducive to better outcome from SARS as a consequence of more effective control of immunopathological lung damage.
Figures
Similar articles
-
Systemic corticosteroids for the treatment of COVID-19.Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 Nov 17;11:CD014963. doi: 10.1002/14651858.CD014963.pub2. PMID: 34396514 Free PMC article. Updated. Review.
-
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2018 Mar 19;3(3):CD006897. doi: 10.1002/14651858.CD006897.pub4. Cochrane Database Syst Rev. 2018. PMID: 29553157 Free PMC article. Review.
-
The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study.J Infect. 2005 Aug;51(2):98-102. doi: 10.1016/j.jinf.2004.09.008. J Infect. 2005. PMID: 16038758 Free PMC article.
-
High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome.Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56. doi: 10.1164/rccm.200306-766OC. Epub 2003 Aug 28. Am J Respir Crit Care Med. 2003. PMID: 12947028
-
Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.Pediatr Crit Care Med. 2003 Jul;4(3):279-83. doi: 10.1097/01.PCC.0000077079.42302.81. Pediatr Crit Care Med. 2003. PMID: 12831407
Cited by
-
The critical impacts of cytokine storms in respiratory disorders.Heliyon. 2024 Apr 17;10(9):e29769. doi: 10.1016/j.heliyon.2024.e29769. eCollection 2024 May 15. Heliyon. 2024. PMID: 38694122 Free PMC article. Review.
-
Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.Front Immunol. 2023 Apr 21;14:1064459. doi: 10.3389/fimmu.2023.1064459. eCollection 2023. Front Immunol. 2023. PMID: 37153613 Free PMC article. Review.
-
Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia.J Int Med Res. 2023 Feb;51(2):3000605221149292. doi: 10.1177/03000605221149292. J Int Med Res. 2023. PMID: 36843426 Free PMC article.
-
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.J Infect Public Health. 2023 Feb;16(2):233-249. doi: 10.1016/j.jiph.2022.12.019. Epub 2022 Dec 29. J Infect Public Health. 2023. PMID: 36603376 Free PMC article. Review.
-
Effect of methylprednisolone treatment on COVID-19: An inverse probability of treatment weighting analysis.PLoS One. 2022 Jun 17;17(6):e0266901. doi: 10.1371/journal.pone.0266901. eCollection 2022. PLoS One. 2022. PMID: 35714141 Free PMC article.
References
-
- Zhong N.S., Zeng G.Q. Our strategies for fighting severe acute respiratory syndrome (SARS) Am J Respir Crit Care Med. 2003;168:7–9. - PubMed
-
- Choi K.W., Chau T.N., Tsang O., Tso E., Chiu M.C., Tong W.L. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003;139:715–723. - PubMed
-
- Lee N., Hui D., Wu A., Chan P., Cameron P., Joynt G.M. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–1994. - PubMed
-
- Ho J.C., Ooi G.C., Mok T.Y., Chan J.W., Hung I., Lam B. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003;168:1449–1456. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous